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One Sentence Summary:  
The CXCL13 trap works to decrease tumor burden in pancreatic cancer by reducing the 
differentiation of B-cells responsible for inhibiting the anti-tumor immune response, shown 
through the expression levels of cytokines measured through western blot and flow cytometry. 
Abstract:  
Introduction: Pancreatic cancer represents around 3% of all cancers in the United States. Despite 
this low incidence, it represents around 7% of all cancer deaths in the United States, making it 
the fourth leading cause of cancer-related death. While prognosis does depend on histologic 
grade and extend of spread, pancreatic cancer is often difficult to treat due to lack of effective 
screening tests, quick spread, recurrence, and low immunogenic nature. Additionally, pancreatic 
cancer, such as its most common form: Pancreatic Ductal Adenocarcinoma (PDAC), is resistant 
to most systemic/targeted therapies. This facilitates the need for novel drug delivery. One such 
novel therapeutic treatment option is traps. Traps are fusion proteins that bind to chemokines in a 
manner similar to monoclonal antibodies. The traps are then formulated into nanoparticles which 
can be delivered to the pancreas. The trap can be formulated to target chemokines like CXCL13 
which has been implicated in the suppression of the anti-tumor response through B-reg 
recruitment. Methods: To analyze the effectiveness of the CXCL13 trap, mouse tumor studies 
were completed, in which KPC98207 cells were injected into the tail of the pancreas. Mice were 
randomized into two treatment groups: PBS or CXCL13 trap nanoparticles. Tumor tissues were 
then harvested to be analyzed through western blot and flow cytometry for the presence of 
certain cytokines (pSTAT3, IL-35, IL-10) and vimentin. Results: The PDAC tumors treated with 
CXCL13 trap had significantly reduced presence of pSTAT3, IL-35, IL-10, and vimentin. 
Conclusion: The CXCL13 trap works to decrease tumor burden in PDAC by reducing 
differentiation of B-cells into B-reg cells, shown by the reduction of cytokines involved in 
inhibiting the anti-tumor immune response (pSTAT3, IL-35, IL-10) and vimentin. Thus, the 
CXCL13 trap presents a new treatment option to be used in conjunction with current 
chemotherapeutic drugs to potentially cure and prevent recurrence of PDAC.  
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Introduction 
Epidemiology 
Within the United States approximately 53,670 patients are diagnosed with pancreatic 
cancer each year, representing around 3% of all cancers in the United States.
1
 Despite this low 
incidence, approximately 43,090 patients will die from pancreatic cancer each year, representing 
around 7% of all cancer-related deaths in the United States.
1
 This makes pancreatic cancer the 
fourth leading cause of cancer-related deaths in the United States.
1
 Additionally, pancreatic 
cancer’s 5-year survival rate is particularly low, with only around 8% of patients expected to 
survive.
1
  
While the cause of pancreatic cancer is complex and multifactorial, cigarette smoking 
and family history are among the most common causes. Cigarette smoking has been linked to 
around 20% of all pancreatic tumors.
2
 Additionally, cancers in those that smoke harbor more 
genetic mutations as compared to those that are non-smokers.
2
 With respect to family history, 
approximately 7-10% of affected individuals have some form of family history.
3
 Additionally, 
first-degree relatives of individuals with familial pancreatic cancer, defined as those with a pair 
of first-degree relatives with pancreatic cancer, have a nine-fold increased risk as compared to 
the general population.
4
 In kindreds, defined as those with three or more first-degree relatives 
with pancreatic cancer, have a 32-fold increased risk as compared to the general population. 
Furthermore, patients with familial pancreatic cancer are at a higher risk for developing 
precancerous lesions and extra-pancreatic cancers as compared to patients with sporadic 
pancreatic tumors.
5
 Pancreatic cancer is also a disease that is associated with advancing age. It 
culminates to a 40-fold increased risk by the age of 80.
6
 Patients with these high-risk factors 
could potentially benefit the most from improved treatment modalities.  
Although prognosis is dependent on histologic grade and extent of spread, pancreatic 
cancer often still has poor prognosis due to a number of factors. Most often is that early detection 
is fairly uncommon.
7
 Signs and symptoms of pancreatic cancer, such as upper abdominal pain, 
yellowing of the skin and eyes, and weight loss, do not typically occur until later stages of the 
disease.
7
 Furthermore, there are no effective screening tests for pancreatic cancer.
8
 Pancreatic 
cancer also tends to spread very quickly as it lies at the junction of a number of structures 
allowing it to spread easily. It often spreads to nearby organs, such as the liver, gallbladder, and 
intestines, even in the early stages of the disease.
8
 Additionally, recurrence is likely. Even after 
surgical resection, pancreatic cancer reoccurs. There is a high rate of systemic, 80%, and local, 
20%, recurrence after surgery alone.
9
 It is also difficult to achieve a wide resection margin due to 
proximity to a number of veins and arteries within the pancreas.
9
 Lastly, the tumors are low or 
non-immunogenic, and typically lack tumor-infiltrating effector lymphocytes.
10
  
Pathophysiology  
The most common form of pancreatic cancer is pancreatic ductal adenocarcinoma 
(PDAC), representing around 85% of all pancreatic neoplasms.
11
 Adenocarcinomas evolve 
through non-invasive precursor lesions, typically pancreatic intraepithelial neoplasias.
12
 These 
then acquire clonally selected genetic and epigenetic alterations.
12
 There are a number of genetic 
abnormalities that can occur in invasive PDAC, including the mutational activation of the KRAS 
oncogene and the inactivation of tumor-suppressor genes such as CDKN2A, TP53, SMAD4, and 
BRCA2.
13
 Other genetic abnormalities include widespread chromosomal losses, gene 
amplifications, and telomere shortening.
14,15
  
Early ductal lesions typically do not present with any genetic alterations. KRAS 
mutations are among the first genetic changes that are detected in the progression series. KRAS 
mutations are prevalent in 30% of early stage lesions.
16
 These mutations increase in frequency 
with disease progression, such that they are present in close to 100% of PDAC tumors.
13
 
Activating mutations in the RAS-family oncogenes result in cellular effects such as proliferation 
induction, survival, and invasion through effector pathway stimulation.
17
  
With respect to the TP53 tumor-suppressor gene mutation, more than 50% of PDAC 
tumors have this mutation present.
13
 It is generally caused by missense alterations and arises in 
the later stages of pancreatic intraepithelial neoplasias. This typically causes significant 
dysplasia, reflecting TP53’s role in preventing malignant progression.16 Loss of TP53 facilitates 
genetic instability that leads to malignancy.
16
  
The tumor microenvironment plays an important role in modulating immune responses 
during cancer progression. Tumor associated fibroblasts (TAF) are a major component of the 
tumor microenvironment and produce a number cytokines that promote initiation, progression, 
metastasis of solid tumors.
18
 In addition, TAFs synthesize extracellular matrix, as well as 
metabolic and immune reprogramming of the tumor microenvironment, which impacts adaptive 
chemoresistance.
19
 TAFs also shape immune cell populations within the tumor 
microenvironment by secreting chemokines such as CXCL13. CXCL13 recruits B cells into the 
tumor microenvironment. Regulatory B cells (B-regs) and total B cells promote cancer growth 
by inhibiting the cytotoxic activity of Th1/CD8+ cells. Additionally, B-regs suppress different 
cell subtypes, such as CD4
+
 T cells, through the secretion of suppressive mediators like TGF-β. 
This facilitates the conversion of CD4
+
 T cells into regulatory T cells (T-regs) which promote 
tumor progression.
20
 As differing B cell subpopulations are recruited to the tumor 
microenvironment, they can acquire immunosuppressive properties within the tumor bed and 
attenuate anti-tumor immune responses by promoting IL-10 and PD-L1 expression.
20
 B-reg 
secretion of IL-10 can also convert dendritic cells into a tolerogenic phenotype, thus attenuating 
anti-tumor immune responses. B cell–macrophage interactions also promote PI3Kγ- and Bruton 
tyrosine kinase (BTK)–dependent macrophage Th2 polarization, leading to immune suppression 
and pancreatic cancer progression.
21 
Current Standards of Treatment 
Standards of treatment vary depending on the patient’s extent of disease at presentation. 
Resectable disease is defined as a pancreatic tumor without involvement of the superior 
mesenteric artery or coeliac axis, a patent superior mesenteric-portal venous confluence, and the 
lack of distant metastatic disease.
22
 Currently, surgical resection is the only curative option for 
pancreatic cancer. Unfortunately as the disease frequently presents late, only 15-20% of patients 
are candidates for pancreatectomy.
23
 Adjuvant chemotherapy is recommended in all patients with 
resected pancreatic cancer. Adjuvant treatment includes gemcitabine +/- capecitabine +/- 
fluorouracil-based chemoradiation.
24
 Gemcitabine is a pyrimidine antimetabolite that works to 
inhibit DNA synthesis through the inhibition of DNA polymerase and ribonucleotide reductase. 
It however is associated with a number of side effects including myelosuppression, pulmonary 
toxicities, nausea and vomiting, edema, hepatotoxicity, and fever.
24
 Capecitabine is a pro-drug of 
fluorouracil, which inhibits thymidylate synthetase, blocking methylation of deoxyuridylic acid 
to thymidylic acid, interfering with DNA synthesis. It again is associated with a number of side 
effects including hand-foot syndrome and GI toxicities.
24
  
Locally advanced, unresectable pancreatic cancer is defined as a tumor that encases a 
vascular structure (ie: superior mesenteric artery, coeliac axis, superior mesenteric vein-portal 
vein confluence) or bulky peripancreatic lymphadenopathy with no evidence of distant 
metastatic disease.
22
 Treatment options include gemcitabine +/- nanoparticle albumin-bound 
paclitaxel (nabpaclitaxel) or FOLFIRINOX (oxaliplatin, leucovorin, irinotecan, fluorouracil, 
FU).
25
 Paclitaxel works by promoting microtubule assembly by enhance the action of tubulin 
dimers, stabilizing existing microtubules, and inhibiting their disassembly. This interferes with 
the late G2 mitotic phase and cell replication. However it does have side effects including 
myelosuppression, peripheral neuropathies, and hypersensitivities.
25
 As FOLFIRINOX is a 
combination of a number of different significant side effects including myelotoxicity, diarrhea, 
mucositis, hand-foot syndrome, and pulmonary toxicities. It is typically only used in those with a 
good performance status and normal total bilirubin.
25
  
As for metastatic disease, depending on performance status and bilirubin levels, 
FOLFIRINOX, FOLFOX, gemcitabine + nabpaclitaxel, gemcitabine + capecitabine, or 
gemcitabine alone.
26
 Palliative care alone may be considered in those with too poor of a 
performance status.
26 
Traps 
 Traps are fusion proteins that are designed to bind to chemokines, such as CXCL13 with 
a high affinity in a manner similar to monoclonal antibodies. Nanoparticles can be used to 
deliver and express the plasmid DNA encoding the trap.  
Importance and Objective 
 PDAC is characterized by the presence of abundant stroma and is resistant to most 
systemic and targeted therapies. Even immunotherapies, including checkpoint inhibitors, are not 
effective against PDAC. Treatment modalities that are effective are not targeted and cause a 
number of toxicities in the patient. The objective is to evaluate a trap against CXCL13’s in its 
potential use in PDAC. As CXCL13 recruits B-reg cells into the tumor microenvironment, by 
blocking CXCL13, B-reg infiltration will be blocked and reduce tumor progression. This 
targeted therapy represents a novel treatment modality for PDAC. Preliminary data has shown 
that the CXCL13 trap (OT1) reduces tumor growth; however its mechanism of action has not yet 
been shown to reduce B-reg differentiation. Thus, the goal is to prove OT1 decreases PDAC 
tumor growth by reducing B-reg differentiation through known marker of B-reg expression. 
Results  
OT1 Decreases pSTAT3, IL-35, and Vimentin Expression 
 After immunoblotting with the corresponding antibodies, OT1 was shown to reduce 
expression of pSTAT3, IL-35, and Vimentin (Fig. 1). Each is a known marker of B-reg 
differentiation. IL-35 is directly secreted by B-reg cells. pSTAT3 is upregulated by IL-10, which 
is secreted by B-reg cells. Vimentin is a general marker of accelerated growth, increased 
invasion, and poor prognosis. After densitometry analysis, OT1 decreases pSTAT3 expression at 
a significance level of p<0.05 (Fig. 2). Additionally, OT1 decreases IL-35 and Vimentin 
expression at a significance level of <0.01 (Fig. 2).  
OT1 Decreases IL-10 Expression 
 IL-10 expression in B-reg cells was analyzed through the use of flow cytometry. 
CD138+CD1d+CD5+ is the specific marker for B-reg cells. After specifically targeting these 
cells in the tumor lysate and utilizing antibodies against IL-10, OT1 was shown to decrease 
expression of IL-10 as compared to placebo (0.79% vs. 8.91% respectively) (Fig. 3). Through 
statistical analysis, OT1 significantly reduced expressed of IL-10 at a level of p<0.01.  
Discussion  
In conclusion, OT1 significantly reduces expression of known markers of B-reg 
expression: pSTAT3, IL-35, Vimentin, and IL-10. This shows that OT1 does reduce B-reg 
differentiation, allow the body to product an anti-tumor response, decreasing tumor progression. 
OT1 offers a new targeted treatment modality to be used alongside current chemotherapy and 
potentially future immunotherapy. Limitations of this study include that marker confirmation 
was only assessed through two methods: western blot and FC, and that other known markers of 
B-reg expression were not assessed (ie: TGF-β, PD-L1, PD-1, and IL-8). Future research 
includes assessing cytokine levels through other methods: RT-PCR, ELISA, and 
immunofluorescence staining; assessing other known markers; and evaluating OT1’s use in other 
models (ie: melanoma).  
Materials and Methods 
Materials 
1,2-distearoryl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol-
2000)] ammonium salt (DSPE-PEG) was purchased from NOF (Ebisu Shibuya-ku, Tokyo). 1,2-
dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP) was purchased from Avanti 
Polar Lipids (Alabaster, AL, USA). Cholesterol and protamine were purchased from Sigma-
Aldrich (St. Louis, MO, USA). DiI for biodistribution studies was purchased from ThermoFisher 
Scientific. All other chemicals were purchased from Sigma-Aldrich if not specifically 
mentioned. 
Methods 
Construction of CXCL13 Trap Genes 
The CXCL13 trap was engineered through a known antibody that binds to human 
CXCL13 by grafting the CDRs into a murine scFv scaffold. In brief, the codon-optimized DNA 
sequences code for a signaling peptide, VH domain, a flexible linker, VL domain, E tag, and 
His(6×) tag, respectively was synthesized. The resulting cDNA was cloned into pCDNA3.1 
between Nhe I and Xho I sites and the accuracy was confirmed by DNA sequencing.  
Expression and Purification of Recombinant Trap Proteins 
CXCL13 trap protein was expressed as previously reported. To express the trap protein, 
56 g of pcDNA3.1-CXCL13 trap plasmid was diluted into 2.5 mL Opti-MEM media in a 50mL 
falcon tube followed by incubation at room temperature for 5 min. In another tube, 46.5 L of 
lipofectamine 2000 (ThermoFisher, Grand Island, NY) was diluted into 2.5 mL Opti-MEM 
media and incubated as above. After mixing plasmid and lipofectamine 2000 solutions, 25 mL 
Opti-MEM was supplemented and incubated at room temperature for 18 min. The mixture was 
then applied to 70-90 % confluent 293T/17 cells in T175 flasks followed by cultivation for 3 
days in a CO2 incubator at 37 C. After protein expression, media was harvested and incubated 
with IMAC Nickel-charged resin (BIORAD, Hercules, CA) equilibrated with the binding buffer 
(25 mL HEPES, 300 mM NaCl, pH 7.4) for 1 h at 4 C. The slurry was packed into a column 
followed by washing with 20 mM and 50 mM imidazole in the binding buffer sequentially. 
Bound trap was eluted with 200 mM imidazole in the binding buffer and dialyzed against PBS at 
4°C.  
Binding Affinity Measurement 
The affinity of CXCL13 trap to CXCL13 was accessed with Microscale Thermophoresis 
(MST). One hundred µL of 200 nM IL-10 trap was first fluorescently labeled by mixing with 
100 L of 100 nM RED-tris-NTA dye followed by incubation at room temperature for 30 min.  
Ten L of the labeled trap was then added to 10 L of serially 2-fold diluted mouse IL-10 or 
other interleukins (Biolegend, San Diego, CA) at 10 M using a PBST buffer (PBS with 0.05 % 
Tween 20). The resulting samples were subsequently loaded into capillaries, and the 
thermophoresis of each sample was measured using Auto Red laser power and medium MST 
power on Monolith NT.115 (NanoTemper Technologie, Munich, Germany).  
Preparation and Characterization of LPD 
LPD NPs were prepared through a stepwise self-assembly process as described 
previously. Briefly, DOTAP and cholesterol (1:1, mol/mol) were dissolved in chloroform, and 
the solvent was removed. The lipid film was then hydrated with distilled water to make the final 
concentration of 10 mM cholesterol and DOTAP. The hydrated lipid suspension was 
sequentially extruded through 200 nm and 100 nm polycarbonate membranes (Millipore, MA) to 
form 70 – 100 nm unilamellar liposomes. The LPD polyplex cores were formulated by mixing 
100 μL of 50 μg protamine in 5 % glucose with equal volume of 50 μg plasmid (plasmids 
encoding CXCL13 trap) in 5 % glucose. The mixture was incubated at room temperature for 10 
min followed by the addition of 60 μL cholesterol/DOTAP liposomes (10 mM each). Post 
insertion of 15 % DSPE-PEG-AEAA was performed at 60 °C for 15 min. The size and surface 
charge of the NPs were determined by a Malvern ZetaSizer Nano series (Westborough, MA). 
TEM images were acquired where NPs were negatively stained with uranyl acetate using a JEOL 
100 CX II TEM (JEOL, Japan). 
Bio-distribution of LPD NPs 
Approximately 0.1 % of hydrophobic dye DiI was incorporated into DOTAP-cholesterol 
liposomes to formulate the DiI-labeled LPD NPs. Twenty-four hours after intravenous injection 
of the DiI-labeled LPD NPs, mice were euthanized, major organs and tumors were collected. The 
distribution of LPD NPs in major organs was quantitatively visualized with IVIS
®
 Kinetics 
Optical System (Perkin Elmer, CA). Images were captured at an excitation wavelength of 520 
nm and emission wavelength of 560 nm.  
Cell Lines and Tissue Cultures 
Mouse KPC cell line (KPC 98027) expressing RFP/Luc was stably transfected with a 
vector carrying the mCherry red fluorescent protein (RFP), firefly luciferase (Luc), and the 
puromycin resistance gene. Stably transfected KPC98027 cells (KPC98027 RFP/Luc) were 
selected in the presence of puromycin.  The cells were cultivated in Dulbecco’s Modified Eagle 
Medium: Nutrient Mixture F-12 (DMEM/F12) supplemented with 10 % fetal bovine serum 
(FBS) (Gibco) and 1 % Penicillin/Streptomycin at 37 °C and 5 % CO2 in a humidified 
atmosphere. 
Orthotopic Allograft KPC Mouse Model 
Six-week-old female C57BL/J mice were purchased from Charles River Laboratories and 
maintained under pathogen-free conditions. All animal handling procedures were approved by 
the University of North Carolina at Chapel Hill’s Institutional Animal Care and Use Committee. 
Sub-confluent KPC98207 (with or without RFP/Luc) cells were harvested and washed with cold 
PBS just prior to implantation. Orthotopic allografting KPC model was established by orthotopic 
injection of 1x10
6
 cells into the tail of pancreas. In brief, eight-week-old C57BL/6 mice were 
anesthetized by 2.5 % isoflurane and placed in supine position. A midline incision was made to 
exteriorize the spleen and pancreas. Using an insulin-gage syringe, 1x10
6
 cells in 50 μL (PBS + 
Matrigel) were injected into the tail of pancreas. The abdominal wall and skin were closed with 
6-0 polyglycolic acid sutures. The injection site was sealed with a tissue adhesive (3M, St. Paul, 
MN) and sterilized with 70 % alcohol. Tumor growth was monitored by intraperitoneal injection 
of 100 µL of D-Luciferin (10 mg/ml) followed by bioluminescence analysis using an IVIS
®
 
Kinetics Optical System (BD, CA). 
Tumor Growth Inhibition and Survival Analysis 
Mice bearing KPC98027 RFP/Luc allografts were established as described above. 
Treatments were initiated on day 18. Mice were then randomized into 4 groups (n = 8 - 10) as 
follows: Untreated group (PBS), CXCL13 trap NP (encapsulated with pcDNA3.1 containing the 
trap gene). Intravenous injections were performed every three days for a total of 3 doses of 50 µg 
plasmid/mice. Tumor growth was monitored using IVIS
®
 Kinetics Optical System (Perkin 
Elmer, CA) every 3 days. The increases of tumor volumes were calculated as the radiance of the 
intensities and standardized with the initial tumor volume (Vt/V0). 
Western Blot Analysis  
 Tumor extracts were separated by SDS-PAGE and transferred onto PVDF membranes. 
These extracts were probed with antibodies against GAPDH, pSTAT3, IL-35, and Vimentin 
(1:1000, Invitrogen). Proteins of interest were detected with HRP-conjugated goat anti-mouse 
IgG antibody (1:4000, Invitrogen) and visualized with the Pierce ECL Western blotting substrate 
(Thermo Scientific), according to the provided protocol.  
Flow cytometry assay 
Tumor-infiltrating immune cells were analyzed by flow cytometry. In brief, tumor tissues 
were harvested and digested with collagenase A and DNase at 37 °C for 60 min. After lysis of 
red blood cells, cells were resuspended in 5 mL of PBS. 2x10
6
 cells were stained with 
fluorescently labeled antibodies for surface marker expression analysis. After staining, cells were 
fixed with 300 μL 4 % PFA and analyzed via FACS (BD LSR II). 
To access cytokine production by tumor infiltrating cells, cells were stained with surface 
marker, washed, fixed and permeabilized using the cytofix/cytoperm kit from BD Pharmingen, 
according to manufacturer's instructions. Intracellular stains were performed using anti-IL-10 
antibody. Cells were washed and analyzed on an 18-color flow cytometer (LSR II). Data was 
analyzed with FlowJo 8.6 software (TreeStar). 
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Figures:  
Fig. 1. pSTAT3, IL-35, Vimentin, and GAPDH Western Blot (n=3) 
 
Fig. 1: Protein expression of pSTAT3, IL-35, vimentin, and GAPDH were detected by 
immunoblotting with the corresponding antibody. Each lane represents a separate mouse treated 
within the specified treatment group. Tumor lysates from the PBS treatment group: Lanes 1-3. 
Tumor lysates from the OT1 treatment group: Lanes 4-6.  
 
 
 
 
 
Fig. 2. Western Blot Densitometry by Selected Markers (n=3) 
 
Fig. 2: WB band intensity quantification through ImageJ software. *denotes p<0.05, **denotes 
p<0.01. a. OT1 reduces pSTAT3 expression. b. OT1 reduces IL-35 expression. c. OT1 reduces 
vimentin expression. d. Similar protein concentrations were loaded in the PBS and OT1 groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. IL-10 Flow Cytometry 
 
Fig. 3: a. 8.91% IL-10 expression by B-reg cells in the PBS treatment group. b. 0.79% IL-10 
expression by B-reg cells in the OT1 treatment group. c. OT1 significantly reduces IL-10 
expression by B-reg cells. **denotes p < 0.01.  
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